Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q3 FY20 results · Oct–Dec 2019
Glenmark Pharmaceuticals reported revenue from operations of ₹2,735.56 crore (up 7.1% from Q3 FY19) and net profit of ₹190.84 crore (up 64.0% from Q3 FY19) for Q3 FY20 (Oct–Dec 2019), on a consolidated basis.
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,735.56 | 2,555.05 | +7.1% | 2,815.04 | −2.8% |
| Other income | 32.96 | (109.02) | Turned profit | 80.83 | −59.2% |
| Total income | 2,768.52 | 2,446.03 | +13.2% | 2,895.86 | −4.4% |
| Profit before tax | 270.98 | 154.03 | +75.9% | 347.30 | −22.0% |
| Net profit for the period | 190.84 | 116.34 | +64.0% | 255.54 | −25.3% |
| EPS, basic (₹) | 13.52 | 4.12 | not comparable | 9.06 | +49.2% |
| Net margin (%) | 7.0 | 4.6 | 9.1 |
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,816.29 | 1,632.04 | +11.3% | 1,789.82 | +1.5% |
| Other income | 94.49 | (84.64) | Turned profit | 192.47 | −50.9% |
| Total income | 1,910.78 | 1,547.39 | +23.5% | 1,982.29 | −3.6% |
| Profit before tax | 410.64 | 183.83 | +123.4% | 474.51 | −13.5% |
| Net profit for the period | 345.53 | 195.87 | +76.4% | 431.99 | −20.0% |
| EPS, basic (₹) | 24.50 | 6.94 | not comparable | 15.31 | +60.0% |
| Net margin (%) | 19.0 | 12.0 | 24.1 |
Consolidated
- Filed with BSE
- 15 Feb 2020, 10:19 IST
- Board meeting
- 14 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 15 Feb 2020, 10:19 IST
- Board meeting
- 14 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE